Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Madrigal Pharmaceuticals Inc Market Cap
The Madrigal Pharmaceuticals Inc (MDGL) share price is expected to increase by 43.13% over the next year. This is based on calculating the average 12-month share price estimate provided by 6 stock analysts who have covered MDGL. Price targets range from $300.00 at the low end to $383.00 at the high end. The current analyst consensus for MDGL is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Madrigal Pharmaceuticals Inc has a total of 6 Wall St Analyst ratings. There are 6 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Madrigal Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| yasmeen rahimi Piper Sandler | Buy | $336.0 | rated | Feb 14, 2024 |
| thomas smith Leerink Partners | Buy | None | reiterated | Feb 8, 2024 |
| jay olson Oppenheimer | Buy | $300.0 | maintained | Feb 7, 2024 |
| akash tewari Jefferies | Buy | $321.0 | maintained | Jan 18, 2024 |
| jonathan wolleben JMP Securities | Buy | $383.0 | reiterated | Jan 8, 2024 |
| eliana merle UBS | Buy | $337.0 | maintained | Dec 29, 2023 |
| liisa bayko Evercore ISI | Buy | $325.0 | maintained | Dec 1, 2023 |
| ritu baral TD Cowen | Buy | $349.0 | maintained | Nov 17, 2023 |
| ed arce H.C. Wainwright | Buy | $275.0 | maintained | Nov 13, 2023 |
| mayank mamtani B.Riley Financial | Hold | $154.0 | maintained | Nov 8, 2023 |
| edward nash Canaccord Genuity | Buy | $336.0 | maintained | Nov 6, 2023 |
| andrea tan Goldman Sachs | Buy | $409.0 | reiterated | Aug 8, 2023 |
| steven seedhouse Raymond James | Hold | None | upgraded | Dec 19, 2022 |
| matthew luchini BMO Capital | Buy | $111.0 | upgraded | Aug 6, 2021 |
| derek archila Wells Fargo | Hold | $130.0 | reiterated | May 6, 2021 |
| salveen richter Goldman Sachs | Hold | $131.0 | maintained | Mar 1, 2021 |
| joel beatty Robert W. Baird | Buy | $155.0 | maintained | Mar 5, 2020 |
| navin jacob UBS | Buy | $127.0 | upgraded | Jan 9, 2020 |
| joshua schimmer Evercore ISI | Buy | $250.0 | maintained | Nov 22, 2019 |
| boris peaker Cowen & Co. | Hold | None | downgraded | Oct 21, 2015 |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
When did it IPO
2007
Staff Count
92
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. William J. Sibold
Market Cap
$4.60B
In 2023, MDGL generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MDGL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
MMSI-USD
$79.45
FELE-USD
$98.07
HCP-USD
$22.69
RCM-USD
$10.87
$34.55
COOP-USD
$72.4
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
